Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sentinel Diagnostics is a private Italian in vitro diagnostics company that develops, manufactures, and commercializes diagnostic reagents, assays, sample-collection systems, and related laboratory solutions for clinical chemistry, immunochemistry, molecular diagnostics, fecal testing, and chromatography-based testing. The company operates commercially and sells products for use in medical analysis laboratories, hospitals, clinics, and other healthcare settings worldwide. Its notable proprietary technologies include the FOB Gold fecal immunochemical testing system and the STAT-NAT lyophilized molecular diagnostics platform. Sentinel has also expanded into chromatography and mass spectrometry diagnostics through the acquisition of Eureka Lab Division. Overall, the company is best characterized as an established commercial IVD manufacturer rather than a therapeutic biotech developer.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sentinel Diagnostics.